Overview

A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-01-31

Target enrollment:

Participant gender:

Summary

This is a Phase 1b/2, open-label, 2-part, global study designed to investigate the anti-tumor activity as well as the safety and efficacy of BAT8006 in subjects with platinum resistance ovarian cancer

Phase:

PHASE1

Details

Lead Sponsor:

Bio-Thera Solutions

Treatments:

Injections